Economic burden of haematological adverse effects in cancer patients: A systematic review

Clinical Drug Investigation

Volumn 27, Issue 6, 2007, Pages 381-396

  Liou, S Y ^a,b   Stephens, J M ^a   Carpiuc, K T ^a   Feng, W ^c   Botteman, M F ^a   Hay, J W ^d  

^a PHARMERIT INTERNATIONAL   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 11;

ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CAREGIVER; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION COST; HUMAN; NEUTROPENIA; OUTPATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SOLID TUMOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNITED STATES;

ANEMIA; ANTINEOPLASTIC AGENTS; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 34249908091     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727060-00002     Document Type: Review

References (57)

1. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005 May 1; 103 (9): 1916-24
2. Cosler LE, Calhoun EA, Agboola O, et al. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004; 24 (4): 488-94
3. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005 September 8; 353 (10): 988-98
4. Donohue R. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncol Nurs Forum 2006 March; 33 (2): 347-52
5. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002 Dec 15; 20 (24): 4636-42
6. Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997 June 19; 336 (25): 1776-80
7. Cantor SB, Elting LS, Hudson Jr DV, et al Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 2003 June 15; 97 (12): 3099-106
8. Aledort LM, Mohandas K. Transfusion requirements in patients with malignancy. Semin Hematol 1996 January; 33 (1 Suppl. 1): 6-9
9. Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001 April; 84 Suppl. 1: 31-7
10. Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005 March; 8 (2): 149-56
11. Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006 August 16; 98 (16): 1108-17
12. Bristol Myers Squibb Co. Dasatinib (SPRYCEL) product information. Princeton (NJ)/ Bristol Myers Squibb Co 2006,
13. Cosler LE, Sivasubramaniam V, Agboola O, et al. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 2005 January; 8 (1): 47-52
14. Calhoun EA, Chang CH, Welshman EE, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001; 6 (5): 441-5
15. Chrischilles EA, Klepser DG, Brooks JM, et al. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy. Pharmacotherapy 2005 May; 25 (5): 668-75
16. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006 May 15; 106 (10): 2258-66
17. Cantor SB, Rubenstein EB, Elting LS, et al. Economic evaluation of management strategies for low risk febrile neutropenic cancer patients [abstract no. 1498]. Proc Am Soc Clin Oncol 1997
18. Del Prete SA, Ryan SP, Jacobson JS, et al. Safety and costs of treating neutropenic fever in an outpatient setting. Conn Med 1999 December; 63 (12): 713-7
19. Gandhi SK, Arguelles L, Boyer JG. Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases. Pharmacotherapy 2001 June; 21 (6): 684-90
20. Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998 Nov; 34 (12): 1857-64
21. Glaspy JA, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993; 29A Suppl. 7: S23-30
22. Glaspy JA, Bleecker GC, Crawford J, et al. Decreased costs in cancer chemotherapy patients using recombinant granulocyte colony stimulating factor. Clin Res 1991; 39 (1): 7A
23. Minisini A, Spazzapan S, Crivellari D, et al. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors. Crit Rev Oncol Hematol 2005 Feb; 53 (2): 125-31
24. Annemans L, Giaccone G, Vergnenegre A. The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. Anticancer Drugs 1999 Jul; 10 (6): 605-15
25. Herold M, Hieke K. Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine. Eur J Health Econ 2002; 3 (3): 166-72
26. Dranitsaris G, Tran TM. Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer 1995; 31A (13-14): 2174-80
27. Dranitsaris G, Tran TM, McGeer A, et al. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics 1995; 7 (1): 49-62
28. Korpela J, Salminen E. Neutropenic infections add significant costs to palliative chemotherapy in breast cancer. Anticancer Res 2002; 22 (2B): 1337-40
29. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93 (1): 31-8
30. Mayordomo JI, Rivera F, az-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995; 87 (11): 803-8
31. Montero MC, Valdivia ML, Carvajal E, et al. Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm World Sci 1994 Aug 5; 16 (4): 187-92
32. Hackshaw A, Sweetenham J, Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma? Br J Cancer 2004; 90 (7): 1302-5
33. Leese B, Collin R, Clark DJ. The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 1994; 6 (3): 233-9
34. Leese B. The costs of treating febrile neutropenia in six U.K. Hospitals. Eur J Cancer 1993; 29A Suppl. 7: S15-8
35. Elting LS, Cantor SB. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer 2002; 10 (3): 189-96
36. Bennett CL, Stinson TJ, Laver JH, et al. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma 2000; 37 (1-2): 65-70
37. Elting LS, Cantor SB, Martin CG, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 2003; 97 (6): 1541-50
38. Malone D, Sullivan S, Black D, et al. The cost of treating chemotherapy-induced thrombocytopenia [abstract no. 887]. Proc Am Soc Clin Oncol 1995
39. Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339 (11): 746-54
40. Snider C, Erder H, LaBrecque J, et al. What are the true costs of platelet transfusions? A prospective time motion study of resource utilization associated with platelet transfusions at UCLA Medical Center [abstract]. Blood 1996; 88: 333a
41. Balducci L, Benson K, Lyman GH, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. Transfusion 1993; 33 (8): 665-70
42. Najib MM, Katz LM, Fastenau J, et al. Costs and epidemiology of myelosuppression in chemotherapy-treated metastatic breast cancer patients [abstract no. 2775]. Blood 2003 Nov 16; 102: 11
43. Berndt E, Crown W, Kallich J, et al. The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics 2005; 23 (2): 183-92
44. Nissenson AR, Wade S, Goodnough T, et al. Economic burden of anemia in an insured population. J Manag Care Pharm 2005; 11 (7): 565-74
45. Ershler WB, Chen K, Reyes EB, et al. Economic burden of patients with anemia in selected diseases. Value Health 2005; 8 (6): 629-38
46. Lyman GH, Berndt E, Crown W, et al. Anemia is associated with high cost in newly diagnosed cancer patients [abstract]. Blood 2001 Nov 16; 98 (11 Part 2): 414b
47. Cersosimo RJ, Jacobson DR. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann Pharmacother 2006; 40 (1): 58-65
48. Cremieux P, Greenberg P, Piech CT. Epoetin alfa is more effective and less costly relative to darbepoetin alfa in lung cancer patients receiving treatment for chemotherapy-induced anemia [abstract no. 2248]. Proc Am Soc Clin Oncol 2003
49. Sheffield R, Sullivan SD, Saltiel E, et al. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997; 31 (1): 15-22
50. Cremieux PY, Finkelstein SN, Berndt ER, et al. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 1999; 16 (5 Pt 1): 459-72
51. Meadowcroft AM, Gilbert CJ, Maravich-May D, et al. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am J Health Syst Pharm 1998; 55 (18): 1898-902
52. Marchetti M, Barosi G. Clinical and economic impact of epoetins in cancer care. Pharmacoeconomics 2004; 22 (16): 1029-45
53. Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. Am J Health Syst Pharm 2005; 62 (24): 2597-603
54. Cremieux PY, Barrett B, Anderson K, et al. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000; 18 (14): 2755-61
55. Cantor SB, Hudson Jr DV, Lichtiger B, et al. Costs of blood transfusion: a process-flow analysis. J Clin Oncol 1998; 16 (7): 2364-70
56. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995 May; 35 (5): 427-30
57. Forbes JM, Anderson MD, Anderson GF, et al. Blood transfusion costs: a multicenter study. Transfusion 1991 May; 31 (4): 318-23